Why did Biden buy this?? Is he expecting nukes about to hit

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
405
Why did Biden buy this?? Is he expecting nukes about to hit the US??

U.S. Stockpiles $290 Million in NIH-Funded Radiation Sickness Drug

The Biden administration this week purchased $290 million worth of Nplate, a radiation sickness drug — with serious side effects — developed by drugmaker Amgen in partnership with several government agencies, including the National Institute of Allergy and Infectious Diseases, headed by Dr. Anthony Fauci. ...

In what pharmaceutical industry publication Fierce Pharma called “a troubling sign of the times,” the Biden administration this week purchased $290 million in anti-radiation drugs.

In an Oct. 4 press release, the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) announced the purchase of Nplate, a drug used to treat acute radiation syndrome.

ASPR — the federal agency tasked with preparing for disasters and public health emergencies — said the purchase was made “as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.”

SOUNDS LIKE BIDEN IS GETTING READY FOR A NUKE WAR!

HHS did not clarify why it bolstered the government’s Nplate stockpile, other than describing it as “part of our ongoing work for preparedness and radiological security.”

Officials downplayed any connection to the Russia-Ukraine conflict, adding that the purchase “was not accelerated by the situation in Ukraine.”

However, two days after the announcement, amid growing tensions related to the conflict between Russia and Ukraine, President Biden said the risk of nuclear “Armageddon” is at its highest since the Cuban Missile Crisis in 1962.

The U.S. government in recent months has made several moves signaling a growing level of nuclear preparedness.

For instance, in late September, the Intelligence Advanced Research Projects Activity launched a new program, — Targeted Evaluation of Ionizing Radiation Exposure — which will investigate methods to detect low doses of ionizing radiation.

According to The Register, the investigation will work to “build a new understanding of the effects of low-dose radiation” through the use of technologies such as artificial intelligence, machine learning, biomarker discovery and analytical biography.

The Ohio State University, the University of Washington, Areté Associates and Signature Science received grants to conduct the research over a three-and-a-half year period. The research will occur at Lawrence Berkeley National Laboratory, Los Alamos National Lab and the Armed Forces Radiobiology Research Institute.

Earlier this summer, New York City authorities raised eyebrows with the release of a 90-second nuclear preparedness public service announcement (PSA), which the New York Times described as “bizarre” and as “well watched,” but “not well received.”

At the time, NPR reported that New York City’s emergency management department “wants residents to be prepared if [a nuclear attack] does occur,” but that the PSA left many of the city’s residents “confused.”

Outside the U.S., countries neighboring Ukraine, such as Poland, reportedly began distributing iodine tablets in response to the threat of nuclear fallout related to the Russia-Ukraine conflict as a result of shelling around the Zaporizhzhia nuclear power plant in Ukraine.

Nplate is the trade name for the drug romiplostim, approved by the U.S. Food and Drug Administration (FDA) in January 2021 for the treatment of blood cell injuries that result from acute radiation syndrome.

The drug is an artificial protein that promotes the production of platelets — or blood-clotting cells — in the human body.

The drug first received FDA approval in 2008, for the treatment of immune thrombocytopenia, an autoimmune disorder that causes serious bleeding.

Amgen, the drug’s manufacturer, developed Nplate in conjunction with the Biomedical Advanced Research and Development Authority, or BARDA, under the auspices of Project BioShield, signed into law in July 2004 by then-president George W. Bush.

Project BioShield, which incentivizes private companies to develop vaccines and countermeasures for biological, chemical, nuclear and radiological threats, provided funding for the latest $290 million purchase by the HHS.

BARDA — another arm of HHS — garnered attention in recent years for its extensive deals with COVID-19 vaccine manufacturers and for its promotion of COVID-19 countermeasures.

In 2020, BARDA promised Moderna up to $483 million to “shepherd” its COVID-19 vaccine through the FDA approval process.

The National Institute of Allergy and Infectious Diseases (NIAID) — headed by Dr. Anthony Fauci — also contributed to the development of Nplate.

For instance, during an April 2018 oversight hearing of the House Appropriations Subcommittee on Labor, Health and Human Services, and Education, Fauci described NIAID’s involvement in the development and promotion of “radiation/nuclear countermeasure candidates,” including Nplate, for FDA approval under the Animal Rule.

According to the FDA, Animal Rule regulations “allow for the approval of drugs and licensure of biological products when human efficacy studies are not ethical and field trials to study the effectiveness of drugs or biological products are not feasible.”

In the case of Nplate, drugs.com states that the effectiveness of the drug for the purposes of treating radiation exposure “was only studied in animals, because it could not be studied in people.”

Also according to drugs.com, Nplate also is associated with several serious potential side effects, including the increased risk of a blood clot or stroke, an increased risk of developing blood cancers and “harmful effects on your bone marrow that may result in serious blood cell disorders.”

The site states that it is “unknown” if Nplate will cause harm to unborn babies.

Amgen, based in Thousand Oaks, California, describes itself as “A worldwide pioneer in biotechnology.”

The company’s board of directors includes members from The Aerospace Corporation, the David H. Koch Institute for Integrative Cancer Research, Northrop Grumman, Phillips 66, the University of California and Walmart.

The newly purchased stockpile will remain in vendor-controlled inventory, HHS said.

https://childrenshealthdefense.org/defender/u...4b9f7d0111

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading